Abstract
Identifying blood-based signatures of brain health and preclinical pathology may offer insights into early disease mechanisms and highlight avenues for intervention. Here, we systematically profiled associations between blood metabolites and whole-brain volume, hippocampal volume, and amyloid-β status among participants of Insight 46 – the neuroscience sub-study of the National Survey of Health and Development (NSHD). We additionally explored whether key metabolites were associated with polygenic risk for Alzheimer’s disease (AD).
Following quality control, concentrations of 1019 metabolites – detected with liquid chromatography-mass spectrometry – were available for 1740 participants at age 60-64. Metabolite data were subsequently clustered into modules of co-expressed metabolites using weighted coexpression network analysis. Accompanying MRI and amyloid-PET imaging data were present for 437 participants (age 69-71). Regression analyses tested relationships between metabolite measures – modules and hub metabolites – and imaging outcomes. Hub metabolites were defined as metabolites that were highly connected within significant (pFDR<0.05) modules or previously identified as a hub for cognition in the same cohort. Regression models included adjustments for age, sex, APOE genotype, lipid medication use, childhood cognition and social factors. Finally, AD polygenic risk scores (PRS), including and excluding the APOE region, were tested for relationships with metabolites and modules that associated (pFDR<0.05) with an imaging outcome (N=1638).
In the fully adjusted model, three lipid modules were associated with a brain volume measure (pFDR<0.05): one enriched in sphingolipids (hippocampal volume: ß=0.14, 95%CI=[0.055,0.23]), one in several fatty acid pathways (whole-brain volume: ß=-0.072, 95%CI=[-0.12,-0.026]), and another in diacylglycerols and phosphatidylethanolamines (whole-brain volume: ß=-0.066, 95%CI=[-0.11,-0.020]). Twenty-two hub metabolites were associated (pFDR<0.05) with an imaging outcome (whole-brain volume: 22; hippocampal volume: 4). Some nominal associations were reported for amyloid-β, and with an AD PRS in our genetic analysis, but none survived multiple testing correction.
Our findings highlight key metabolites, with functions in membrane integrity and cell signalling, that associated with structural brain measures in later life. Future research should focus on replicating this work and interrogating causality.
Competing Interest Statement
MAS is currently a full-time employee of F. Hoffman-La Roche AG. However, her contributions to this research precede in time and are unrelated to her present employment. J.M.S. has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, Merck, and Eli Lilly, given educational lectures sponsored by GE Healthcare, Eli Lilly, and Biogen. He is Clinical Advisor to UK DRI and Chief Medical Officer for ARUK.
Funding Statement
This study is principally funded by grants from Alzheimer's Research UK (ARUK-PG2014-1946, ARUK-PG2017-1946), the Medical Research Council Dementias Platform UK (CSUB19166), the Wolfson Foundation (PR/ylr/18575), and the Alzheimer's Association (SG-666374-UK). The genetic analyses are funded by the Brain Research Trust (UCC14191). Florbetapir amyloid tracer was kindly provided by Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly. The NSHD is funded by the Medical Research Council (MC_UU_00019/1, MC_UU_00019/3). This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the National Research Ethics Service Committee London (14/LO/1173). All participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Update formatting
Data Availability
Anonymised data are available upon request to bona fide researchers (https://skylark.ucl.ac.uk/NSHD/doku.php).
Abbreviations
- Aβ
- amyloid-beta
- AD
- Alzheimer’s disease
- BMI
- body mass index
- DAG
- diacylglycerol
- FDR
- false discovery rate
- FLAIR
- weighted fluid-attenuated inversion recovery
- KEGG
- Kyoto Encyclopaedia of Genes and Genomes
- kME
- module membership
- LCMS
- liquid chromatography-mass spectrometry
- MR
- Mendelian randomisation
- n3 and n6
- Omega 3 and 6
- NSHD
- National Survey of Health and Development
- PC
- phosphatidylcholine
- PE
- phosphatidylethanolamine
- PRS
- polygenic risk score
- PUFA
- polyunsaturated fatty acid
- QC
- quality control
- SEP
- socioeconomic position
- SUVR
- standardised uptake volume ratio
- WGCNA
- weighted gene coexpression network analysis
